Uterine Transposition: Feasibility Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03040921|
Recruitment Status : Active, not recruiting
First Posted : February 2, 2017
Last Update Posted : January 14, 2020
|Condition or disease||Intervention/treatment||Phase|
|Postoperative Complications Intraoperative Complications Tissue Damage Ovarian Failure Uterus Disorder||Procedure: Uterine transposition.||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Recruitment completed. Final data collection in April/2020.|
|Masking:||None (Open Label)|
|Official Title:||Uterine Transposition: Feasibility Study|
|Actual Study Start Date :||June 1, 2017|
|Actual Primary Completion Date :||June 1, 2019|
|Estimated Study Completion Date :||April 1, 2020|
Experimental: Uterine Transposition
Patients submitted to uterine transposition.
Procedure: Uterine transposition.
Surgical transposition of the uterus to the upper abdomen. After the end of radiotherapy, rectosigmoidectomy is performed and the uterus is repositioned into the pelvis.
- Uterine preservation after transposition to the upper abdomen and replacement in the pelvis [ Time Frame: 6 months ]The preservation of the uterus with normal endometrium confirmed by ultra-sound, after the surgery to place it in the upper abdomen and after replacing the uterus back to its normal position.
- Morbidity [ Time Frame: 6 months ]Intraoperative and postoperative complications
- Cancer recurrence [ Time Frame: Through study completion, an average of 2 years ]Local and distant recurrences
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03040921
|Erasto Gaertner Hospital|
|Curitiba, Parana, Brazil, 81.520-060|
|Principal Investigator:||Reitan Ribeiro, MD||Erasto Gaertner Hospital|